Vanda Pharmaceuticals (VNDA) Revenue Growth (3y) (2013 - 2026)

Vanda Pharmaceuticals (VNDA) Revenue Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 50.07%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.94%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 4.47%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.44%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Vanda Pharmaceuticals 310.98 Mn 108.67 Mn 48.56 Mn -6.12%

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.12%
Dec 31, 2025 -3.91%
Sep 30, 2025 -4.86%
Jun 30, 2025 -6.53%
Mar 31, 2025 -5.97%
Dec 31, 2024 -7.87%
Sep 30, 2024 -12.07%
Jun 30, 2024 -9.41%
Mar 31, 2024 -8.85%
Dec 31, 2023 -12.53%
Sep 30, 2023 -13.66%
Jun 30, 2023 -9.53%
Mar 31, 2023 2.52%
Dec 31, 2022 1.91%
Sep 30, 2022 3.17%
Jun 30, 2022 2.92%
Mar 31, 2022 8.05%
Dec 31, 2021 8.64%
Sep 30, 2021 12.57%
Jun 30, 2021 12.77%